But, he says, that shouldn't be done at the cost of getting ARVs to everyone who needs them.

　　"The issue of whether to use viral-load monitoring or not pales into insignificance when dealing with whether you've actually got everyone who needs ARVs on therapy. Having drugs without viral-load monitoring is a lot better than not having drugs."